Urge your members of Congress to support continued medical research funding
Stephanie Lee, MD, MPH, a highly regarded expert in graft-versus-host disease as well as blood and bone marrow diseases, will serve as president of the American Society of Hematology for a year-long term through December 2020.
People with metabolic syndrome – a set of conditions including obesity, impaired glucose metabolism, elevated levels of fats and cholesterol in the blood, and high blood pressure – are more likely to experience recurrent blood clots, according to a new study published today in Blood Advances.
A new study provides convincing evidence that the use of peripherally inserted central catheters (PICCs) to administer medicine and draw blood in children is associated with a significantly increased risk of blood clots (known as venous thromboembolism or VTE) compared with central venous catheters (CVCs) placed directly into the neck or chest.
Yesterday, the American Society of Hematology (ASH) sent a letter to President Trump outlining concerns with a proposed policy that would jeopardize the intellectual property of American organizations engaged in the creation of high-quality peer-reviewed journals and research articles. The Administration is considering an Executive Order that would mandate that scientific articles reporting on federally funded research be made immediately available to everyone upon publication, eliminating or reducing the current 12-month embargo period that has been in place since 2008.
ASH today announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators.
On Monday, bipartisan leaders in the House and Senate reached an agreement on a $1.3 trillion federal spending deal for fiscal year 2020. The legislation package – which Congress is expected to pass and then submit to President Trump for signature this week – includes increased funding for vital public health agencies.
Three adult patients with sickle cell disease (SCD) are doing well after receiving an infusion of their own stem cells that had been genetically engineered to induce them to stop producing harmful “sickle” hemoglobin and start producing a healthy form of hemoglobin, according to a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.
Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando.
Patients with cold agglutinin disease (CAD) had improved hemoglobin levels, required fewer blood transfusions, and felt significantly less fatigued after receiving the experimental drug sutimlimab for 26 weeks in a phase III clinical trial.
Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology